Identification of ellagic acid as potent inhibitor of protein kinase CK2: A successful example of a virtual screening application

Journal of Medicinal Chemistry

Volumn 49, Issue 8, 2006, Pages 2363-2366

  Cozza, Giorgio ^a   Bonvini, Paolo ^a   Zorzi, Elisa ^a   Poletto, Giorgia ^a   Pagano, Mario A ^a   Sarno, Stefania ^a   Donella Deana, Arianna ^a   Zagotto, Giuseppe ^a   Rosolen, Angelo ^a   Pinna, Lorenzo A ^a   Meggio, Flavio ^a   Moro, Stefano ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE II; ELLAGIC ACID; PROTEIN KINASE; TANNIN DERIVATIVE;

ARTICLE; CARCINOGENESIS; COMPLEX FORMATION; KINETICS; PROTEIN ANALYSIS; PROTEIN STRUCTURE;

BINDING SITES; CASEIN KINASE II; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; ELLAGIC ACID; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; KINETICS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646082261     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060112m     Document Type: Article

References (28)

1. Meggio, F.; Pinna, L. A. One-thousand-and-one substrates of protein kinase CK2? FASEB J. 2003, 17, 349-368.
2. Litchfield, D. W. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J. 2003, 569, 1-15.
3. Seldin, D. C.; Leder, P. Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle. Science 1995, 267, 894-897.
4. Kelliher, M. A.; Seldin, D. C.; Leder, P. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha. EMBO J. 1996, 15, 5160-5166.
5. Landesman-Bollag, E.; Channavajhala, P. L.; Cardiff, R. D.; Seldin, D. C. p53 deficiency and misexpression of protein kinase CK2alpha collaborate in the development of thymic lymphomas in mice. Oncogene 1998, 16, 2965-2974.
6. Orlandini, M.; Semplici, F.; Ferruzzi, R.; Meggio, F.; Pinna, L. A.; Oliviero, S. Protein kinase CK2alpha is induced by serum as a delayed early gene and cooperates with Ha-ras in fibroblast transformation. J. Biol. Chem. 1998, 273, 21291-21297.
7. Guo, C.; Yu, S.; Wang, H.; Davis, A. T.; Green, J. E.; Ahmed, K. A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells. J. Biol. Chem. 2001, 276, 5992-5999.
8. Tawfic, S.; Yu, S.; Wang, H.; Faust, R.; Davis, A.; Ahmed, K. Protein kinase CK2 signal in neoplasia. Histol. Histopathol. 2001, 16, 573-582.
9. Unger, G. M.; Davis, A. T.; Slaton, J. W.; Ahmed, K. Protein kinase CK2 as regulator of cell survival: implications for cancer therapy. Curr. Cancer Drug. Targets 2004, 4, 77-84.
10. De Moliner, E.; Moro, S.; Sarno, S.; Zagotto, G.; Zanotti, G.; Pinna, L. A.; Battistutta, R. Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight. J. Biol. Chem. 2003, 278, 1831-1836.
11. Meggio, F.; Pagano, M. A.; Moro, S.; Zagotto, G.; Ruzzene, M.; Sarno, S.; Cozza, G.; Bain, J.; Elliott, M.; Deana, A. D.; Brunati, A. M.; Pinna, L. A. Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. Biochemistry 2004, 43, 12931-12936.
12. Vangrevelinghe, E.; Zimmermann, K.; Schoepfer, J.; Portmann, R.; Fabbro, D.; Furet, P. Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. J. Med. Chem. 2003, 19, 2656-2662.
13. Toledo-Sherman, L.; Deretey, E.; Slon-Usakiewicz, J. J.; Ng, W.; Dai, J. R.; Foster, J. E.; Redden, P. R.; Uger, M. D.; Liao, L. C.; Pasternak, A.; Reid, N. Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening. J. Med. Chem. 2005, 48, 3221-3230.
14. Schneider, G.; Bohm, H. J. Virtual screening and fast automated docking methods. Drug Discovery Today 2002, 7, 64-70.
15. Miteva, M. A.; Lee, W. H.; Montes, M. O.; Vilkmtreix, B. O. Fast structure-based virtual ligand screening combining FRED, DOCK, and Surflex. J. Med. Chem. 2005, 48, 6012-6022.
16. Molecular Operating Environment (MOE 2004.03), C. C. G., Inc, 1255 University St., Suite 1600, Montreal, Quebec, Canada, H3B 3X3.
17. Schrodinger, I.; Schrodinger, Inc.: Portland, OR, 2001.
18. McGann, M.; Almond, H.; Nicholls, A.; Grant, J. A.; Brown, F. Gaussian docking functions. Biopolymers 2003, 68, 76-90.
19. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
20. Wang, R.; Lai, L.; Wang, S. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J. Comput.-Aid. Mol. Des. 2002, 16, 11-26.
21. Wang, B. H.; Lu, Z. X.; Polya, G. M. Inhibition of eukaryote serine/threonine-specific protein kinases by piceatannol. Planta Med. 1998, 64, 195-199.
22. Nepka, C.; Asprodini, E.; Kouretas, D. Tannins, xenobiotic metabolism and cancer chemoprevention in experimental animals. Eur. J. Drug Metab. Pharmacokinet. 1999, 24, 183-189.
23. Stoner, G. D.; Mukhtar, H. Polyphenols as cancer chemopreventive agents. J. Cell. Biochem. Suppl. 1995, 22, 169-180.
24. Bhosle, S. M.; Huilgol, N. G.; Mishra, K. P. Enhancement of radiation-induced oxidative stress and cytotoxicity in tumor cells by ellagic acid. Clin. Chim. Acta 2005, 359, 89-100.
25. Falsaperla, M.; Morgia, G.; Tartarone, A.; Ardito, R.; Romano, G. Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. Eur. Urol. 2005, 47, 449-454.
26. Han, C.; Ding, H.; Casto, B.; Stoner, G. D.; D'Ambrosio, S. M. Inhibition of the growth of premalignant and malignant human oral cell lines by extracts and components of black raspberries. Nutr. Cancer 2005, 51, 207-217.
27. Li, T. M.; Chen, G. W.; Su, C. C.; Lin, J. G.; Yeh, C. C.; Cheng, K. C.; Chung, J. G.; Ellagic acid induced p53/p21 expression, G1 arrest and apoptosis in human bladder cancer T24 cells. Anticancer Res. 2005, 25, 971-979.
28. Narayanan, B. A.; Geoffroy, O.; Willingham, M. C.; Re, G. G.; Nixon, D. W. p53/p21 (WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cells. Cancer Lett. 1999, 136, 215-221.